Changes in gut microbiome following anti-tuberculosis treatment: a prospective cohort from eastern China

作者：Simin Zhang, Zhipeng Xu, Zhan Wang, Xinru Fei, Zhongqi Li, Limei Zhu, Leonardo Martínez, Jianming Wang, Qiao Liu · 发表于：BMC Infectious Diseases · 年份：2025 · DOI：10.1186/s12879-025-10800-1 · 被引用次数：6 · 研究领域：Gut microbiota and health、Clostridium difficile and Clostridium perfringens research、Tuberculosis Research and Epidemiology

BACKGROUND: The treatment of people with tuberculosis necessitates the administration of both broad-spectrum and narrow-spectrum antibiotics for a minimum duration of six months. Prolonged antibiotic therapy may result in dysregulation of the gut microbiota, potentially influencing the onset and progression of tuberculosis. There is a paucity of studies focus on the characteristics of gut microbiota changes at various time points during tuberculosis treatment. This study aims to elucidate the relationship between the composition of gut microbiota and their stage within anti-tuberculosis therapy. METHODS: A multi-center, observational prospective cohort study was conducted at four designated hospitals in Jiangsu Province in eastern China. The Gastrointestinal Symptom Rating Scale was employed to evaluate the gastrointestinal discomfort experienced during anti-tuberculosis treatment. Fecal samples were collected at baseline before initiating anti-tuberculosis therapy and at the end of 2 months and 6 months during treatment. Total microbial genomic DNA was extracted and sequenced. Rarefaction curves and alpha diversity indices including observed operational taxonomic units, Chao1 richness and Shannon index were calculated. RESULTS: From October 2020 to December 2022, a total of 204 people with tuberculosis were diagnosed. Among these, 85 people with tuberculosis provided baseline, 2-month, and 6-month fecal samples. The average age was 41.8 ± 15.193 years, with a gender ratio of...